Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Rivastigmine in the Management of Toxic Anticholinergic Delirium: A Prospective Study at Alexandria Poison Center

NCT07545382 is registered in ClinicalTrials.gov with Alexandria University as lead sponsor.

NCT NCT07545382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07545382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Rivastigmine in the Management of Toxic Anticholinergic Delirium: A Prospective Study at Alexandria Poison Center
Lead sponsor
Alexandria University
Phase
Phase 4
Overall status
Completed
Start date
December 8, 2025
Completion date
April 15, 2026
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anticholinergic delirium, antipsychotic toxicity, clozapine poisoning, cns depression, hypoactive delirium, procyclidine induced delirium, tricyclic antidepressant poisoning